- Investing.com
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin’s lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Pipeline Progress | Explore Cellectis's advancements in CAR T therapies, with UCART22 and UCART20x22 programs showing promise in hematological cancers and lymphoma |
Strategic Partnerships | Delve into Cellectis's collaborations with AstraZeneca, Servier, and Allogene, potentially unlocking billions in milestone payments and royalties |
Financial Fortitude | Learn how Cellectis strengthened its cash position to $264 million, extending its runway to mid-2027 and supporting ongoing R&D efforts |
Market Valuation | Analyst price targets range from $3 to $10, suggesting potential upside despite recent stock volatility and a 51% decline over the past yea |
Metrics to compare | CLLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLLSPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.2x | −0.9x | −0.5x | |
PEG Ratio | −0.06 | −0.05 | 0.00 | |
Price/Book | 1.7x | 2.7x | 2.6x | |
Price / LTM Sales | 3.5x | 2.9x | 3.3x | |
Upside (Analyst Target) | 89.4% | 30.4% | 42.4% | |
Fair Value Upside | Unlock | 29.0% | 7.2% | Unlock |